Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Larimar Therapeutics to post earnings of ($0.42) per share for the quarter.
Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Larimar Therapeutics Stock Performance
LRMR stock traded up $0.11 during trading on Friday, hitting $2.97. 2,138,575 shares of the company's stock traded hands, compared to its average volume of 729,529. The business has a fifty day simple moving average of $2.36 and a 200 day simple moving average of $4.23. Larimar Therapeutics has a 52 week low of $1.61 and a 52 week high of $11.20. The stock has a market capitalization of $190.16 million, a price-to-earnings ratio of -2.58 and a beta of 0.91.
Wall Street Analyst Weigh In
Several research analysts recently commented on LRMR shares. HC Wainwright lifted their price target on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, March 25th. Guggenheim reissued a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Truist Financial initiated coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They set a "buy" rating and a $18.00 price objective on the stock. Finally, Robert W. Baird dropped their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $19.63.
Check Out Our Latest Stock Report on LRMR
About Larimar Therapeutics
(
Get Free Report)
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Featured Stories
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
